MedPath

Clinical Trial News

World's First HLA-G Targeted Exosome Therapy SOB100 Receives FDA Approval for Phase I Cancer Trials

FDA Approval
  • SOB100, developed by China Medical University Hospital and Shine-On Biomedical, represents the world's first exosome-based drug delivery platform specifically targeting HLA-G for cancer treatment.
  • The FDA approved Phase I clinical trials for SOB100 on March 8, 2025, following promising preclinical results in aggressive cancers including breast cancer and glioblastoma.
  • The platform uses nanobody technology to deliver therapeutic agents across the blood-brain barrier while minimizing systemic toxicity compared to conventional chemotherapy.
  • Shine-On Biomedical has been recognized as one of the top 10 global developers of exosome-based therapies and has established international partnerships for commercial expansion.

Circuit Clinical and Lightship Merge to Transform Clinical Trial Access and Delivery

  • Circuit Clinical Solutions and Lightship Inc. announced a strategic merger to create a unified clinical trial delivery platform combining hybrid trial models with community-based site networks.
  • The merged organization will offer expanded reach through physical site networks and remote delivery capabilities, supporting traditional, hybrid, and fully virtual trial models.
  • David MacMurchy and Dr. Irfan Khan will serve as co-CEOs of the new entity, which aims to accelerate patient enrollment timelines and enhance accessibility for diverse patient populations.
  • The combination represents a significant consolidation effort in the fragmented clinical research industry, establishing new standards for scale, accessibility, and innovation in trial delivery.

Genetic Factors Drive Early B Cell Repletion After Anti-CD20 Therapy in African American MS Patients

  • A study of 43 African American multiple sclerosis patients found that 20 patients experienced early B cell repletion after anti-CD20 therapy, with genetic polymorphisms in immune system pathways contributing to faster B cell recovery.
  • Genetic analysis identified 1,887 single nucleotide polymorphisms (SNPs) overrepresented in early repleters, with pathway enrichment showing involvement in B cell differentiation, leukocyte activation, and inflammatory response mechanisms.
  • Despite faster B cell repletion, early repleter patients showed similar clinical outcomes to normal repleters, with comparable relapse rates and MRI lesion formation during anti-CD20 treatment.
  • The findings suggest that genetic variations affecting B cell survival and activation pathways may require personalized dosing strategies for anti-CD20 therapies in African American MS patients.

WuXi Biologics Breaks Ground on China's First Dual-Chamber Lyophilization Manufacturing Site in Chengdu

  • WuXi Biologics has commenced construction of a 95,000 square meter microbial manufacturing facility in Chengdu, featuring China's first dual-chamber lyophilization production line.
  • The facility will house a 15,000L fermenter with expansion potential to 60,000L, enabling production of 80-110 drug substance batches annually and over 10 million vials of drug product.
  • The site will utilize WuXi's EffiX™ microbial expression platform to manufacture diverse biologics including peptides, antibody fragments, and virus-like particles for global commercial distribution.
  • Initial production will focus on VISEN Pharmaceuticals' Lonapegsomatropin, a long-acting growth hormone therapy for pediatric growth hormone deficiency, with GMP release scheduled for late 2026.

Nivolumab Plus Chemotherapy Demonstrates Five-Year Survival Benefit in Resectable NSCLC

  • Nivolumab combined with chemotherapy has shown significant overall survival benefit at five years for patients with resectable non-small cell lung cancer.
  • The neoadjuvant use of nivolumab alongside chemotherapy provides improved outcomes compared to traditional approaches in this patient population.
  • Long-term study data solidifies the combination therapy's position as a standard care option for resectable NSCLC patients.
  • The sustained survival benefits over an extended period offer new insights into treatment strategies for individuals with this form of lung cancer.

Novel Therapeutic Classes Transform Future Treatment Paradigm for Metastatic Castration-Resistant Prostate Cancer

Precision Medicine
  • The future of metastatic castration-resistant prostate cancer (mCRPC) treatment is evolving with novel drug classes including radioligand therapies, PROTACs, and immunotherapy approaches showing promising clinical potential.
  • Precision medicine approaches utilizing comprehensive tumor sequencing will enable personalized combination regimens targeting specific mutations and surface proteins to maximize effectiveness while reducing adverse effects.
  • Treatment selection increasingly depends on prior androgen receptor pathway inhibitor (ARPI) exposure, with ARPI-naive patients representing a substantial portion in community settings who may benefit from these agents at mCRPC diagnosis.
  • The ultimate goal is achieving durable disease control through rational combinations that allow longer treatment breaks and reduced medical facility time while preserving patient independence and quality of life.

Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

NCT02200614CompletedPhase 3
Bayer
Posted 9/12/2014

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

NCT03732820Active, Not RecruitingPhase 3
AstraZeneca
Posted 10/31/2018

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

NCT06629779RecruitingPhase 3
Pfizer
Posted 10/22/2024

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

NCT06551324RecruitingPhase 3
Pfizer
Posted 10/21/2024

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

NCT03395197Active, Not RecruitingPhase 3
Pfizer
Posted 12/18/2017

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

NCT03748641Active, Not RecruitingPhase 3
Janssen Research & Development, LLC
Posted 1/25/2019

Mevrometostat Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

NCT03460977RecruitingPhase 1
Pfizer
Posted 4/17/2018

Sequencing Abiraterone and Enzalutamide in mCRPC

NCT02125357CompletedPhase 2
British Columbia Cancer Agency
Posted 9/1/2014

Lipocine's Partner Files New Drug Submission for TLANDO in Canada, Targeting 700,000 Annual TRT Prescriptions

Drug Approval
  • Verity Pharma, Lipocine's licensing partner, has filed a New Drug Submission for TLANDO in Canada, marking a key regulatory milestone for the first FDA-approved oral testosterone replacement therapy that requires no dose titration.
  • The Canadian market represents a significant commercial opportunity with over 700,000 testosterone replacement therapy prescriptions written annually, approximately 50% covered by private insurance.
  • Limited promotional activities for existing TRT options in Canada could provide TLANDO with an opportunity to capture substantial market share in this large and growing therapeutic area.

University of Arizona Researchers Identify Drug Candidate That Reverses Heart Failure Progression in Mouse Models

Drug Discovery
  • Researchers at the University of Arizona's Sarver Heart Center have identified a potential drug candidate that may reverse the progression of a challenging form of heart failure in mouse models.
  • The study, published in Cell Metabolism, focused on addressing a specific type of heart failure known for its limited treatment options and high medical burden.
  • While the findings are preliminary and based on animal studies, they highlight potential avenues for future clinical research aimed at improving outcomes for patients with similar cardiac challenges.
  • The research marks a significant step toward expanding therapeutic possibilities for individuals affected by this difficult-to-treat condition.

Nutriband Secures New U.S. Patent for AVERSA Abuse-Deterrent Transdermal Technology

  • Nutriband Inc. received U.S. Patent 12,318,492 for its AVERSA abuse-deterrent transdermal technology, expanding intellectual property protection for transdermal patches that prevent drug abuse and misuse.
  • The AVERSA technology incorporates aversive agents into transdermal patches and is protected by patents in 46 countries worldwide, including major markets like the United States, Europe, Japan, and China.
  • The company's lead product, Aversa Fentanyl, could become the first abuse-deterrent pain patch on the market with estimated peak annual U.S. sales of $80-200 million.
  • This technology addresses critical safety concerns with transdermal drugs susceptible to abuse while maintaining accessibility for patients who legitimately need these medications.

Metsera's MET-233i Achieves 8.4% Weight Loss in Phase 1 Trial, Enabling First Monthly Amylin-GLP-1 Combination

  • Metsera's MET-233i demonstrated up to 8.4% placebo-subtracted weight loss at Day 36 in a Phase 1 trial of 80 participants with overweight or obesity.
  • The ultra-long acting amylin analog showed a 19-day half-life, supporting once-monthly dosing and potential combination with Metsera's GLP-1 receptor agonist MET-097i.
  • The drug exhibited favorable tolerability with no safety signals, positioning it as a potential first-in-class monthly multi-NuSH combination therapy.
  • Metsera plans to advance MET-233i in ongoing monotherapy and combination trials, with topline data expected in late 2025 and early 2026.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.